Martinsried/Munich, July 13, 2005
MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) announced today that the Company achieved first place in the TecDAX segment of the 2005 Annual Corporate Governance Survey conducted by ergo Kommunikation. MorphoSys achieved a top rating for the second year running, and was also ranked the number one biotechnology company listed on the Frankfurt stock exchange. In the 'Small and Mid Caps' category, which includes SDAX, MDAX and TecDAX companies, MorphoSys ranked within the top five for the third year in a row.The study is conducted annually to compare the implementation of the German Corporate Governance Code and numerous other aspects of investor relations. The 160 companies surveyed are listed in selected indices of the Deutsche Börse and include 40 small caps from the Prime and General Standard segments. The complete study can be viewed on-line at www.ergo-pr.de.
'We are very pleased to have been again recognized for corporate governance excellence at MorphoSys. Corporate Governance has long been an important topic for us, and as such, plays a prominent role in our Company', stated Dave Lemus, Chief Financial Officer of MorphoSys AG.